WO2000008202A3 - 3-methylidenyl-2-indolinone modulators of protein kinase - Google Patents

3-methylidenyl-2-indolinone modulators of protein kinase Download PDF

Info

Publication number
WO2000008202A3
WO2000008202A3 PCT/US1999/017845 US9917845W WO0008202A3 WO 2000008202 A3 WO2000008202 A3 WO 2000008202A3 US 9917845 W US9917845 W US 9917845W WO 0008202 A3 WO0008202 A3 WO 0008202A3
Authority
WO
WIPO (PCT)
Prior art keywords
methylidenyl
protein kinase
indolinone
modulators
prodrugs
Prior art date
Application number
PCT/US1999/017845
Other languages
French (fr)
Other versions
WO2000008202A9 (en
WO2000008202A2 (en
Inventor
Peng Cho Tang
Li Sun
Todd Anthony Miller
Congxin Liang
Ngoc My Tran
Anh Thi Nguyen
Asaad Nematalla
Original Assignee
Sugen Inc
Peng Cho Tang
Li Sun
Todd Anthony Miller
Congxin Liang
Ngoc My Tran
Anh Thi Nguyen
Asaad Nematalla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc, Peng Cho Tang, Li Sun, Todd Anthony Miller, Congxin Liang, Ngoc My Tran, Anh Thi Nguyen, Asaad Nematalla filed Critical Sugen Inc
Priority to AU54684/99A priority Critical patent/AU5468499A/en
Priority to CA002383623A priority patent/CA2383623A1/en
Priority to JP2000563824A priority patent/JP2002522452A/en
Priority to US09/762,198 priority patent/US6531502B1/en
Publication of WO2000008202A2 publication Critical patent/WO2000008202A2/en
Publication of WO2000008202A3 publication Critical patent/WO2000008202A3/en
Publication of WO2000008202A9 publication Critical patent/WO2000008202A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
PCT/US1999/017845 1998-01-21 1999-08-04 3-methylidenyl-2-indolinone modulators of protein kinase WO2000008202A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU54684/99A AU5468499A (en) 1998-08-04 1999-08-04 3-methylidenyl-2-indolinone modulators of protein kinase
CA002383623A CA2383623A1 (en) 1998-08-04 1999-08-04 3-methylidenyl-2-indolinone modulators of protein kinase
JP2000563824A JP2002522452A (en) 1998-08-04 1999-08-04 Regulator of protein kinase 3-methylidenyl-2-indolinone
US09/762,198 US6531502B1 (en) 1998-01-21 1999-08-04 3-Methylidenyl-2-indolinone modulators of protein kinase

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US12925698A 1998-08-04 1998-08-04
US09/129,256 1998-08-04
US9547098P 1998-08-05 1998-08-05
US60/095,470 1998-08-05
US10217898P 1998-09-28 1998-09-28
US60/102,178 1998-09-28
US11610799P 1999-01-15 1999-01-15
US60/116,107 1999-01-15

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09762198 A-371-Of-International 1999-08-04
US09/762,198 A-371-Of-International US6531502B1 (en) 1998-01-21 1999-08-04 3-Methylidenyl-2-indolinone modulators of protein kinase
US10/383,690 Division US6855730B2 (en) 1998-08-05 2003-03-10 3-methylidenyl-2-indolinone modulators of protein kinase

Publications (3)

Publication Number Publication Date
WO2000008202A2 WO2000008202A2 (en) 2000-02-17
WO2000008202A3 true WO2000008202A3 (en) 2000-05-18
WO2000008202A9 WO2000008202A9 (en) 2000-07-27

Family

ID=27492796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017845 WO2000008202A2 (en) 1998-01-21 1999-08-04 3-methylidenyl-2-indolinone modulators of protein kinase

Country Status (4)

Country Link
JP (1) JP2002522452A (en)
AU (1) AU5468499A (en)
CA (1) CA2383623A1 (en)
WO (1) WO2000008202A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777417B2 (en) 2001-09-10 2004-08-17 Sugen, Inc. 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6153634A (en) * 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
CN1138773C (en) 1998-12-17 2004-02-18 霍夫曼-拉罗奇有限公司 4-alkenyl (and alkynyl) oxindoles as inhibitors of cell cycle protein dependent kinases, in particular CDK2
CA2354402A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4,5-pyrazinoxindoles as protein kinase inhibitors
TR200101858T2 (en) 1998-12-17 2001-12-21 F.Hoffmann-La Roche Ag 4-aryloxindoles as JNK protein kinase inhibitors
ES2367007T3 (en) * 1999-11-24 2011-10-27 Sugen, Inc. INDONINABLE DERIVATIVES OF INDOLINONA AND ITS USE AS PTK BINDERS.
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
US20020028828A1 (en) 2000-05-02 2002-03-07 Chung-Chen Wei (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6706709B2 (en) 2000-06-02 2004-03-16 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
PE20020776A1 (en) * 2000-12-20 2002-08-22 Sugen Inc INDOLINONES 4-ARIL SUBSTITUTED
JP2004529110A (en) 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ Indole derivatives with vascular damage activity
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
US6797725B2 (en) 2001-04-09 2004-09-28 Sugen, Inc. Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
KR20040000507A (en) * 2001-05-24 2004-01-03 야마노우치세이야쿠 가부시키가이샤 3-Quinoline-2-(1H)-Ylideneindolin-2-One Derivatives
US6599902B2 (en) 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
ES2275021T3 (en) * 2001-09-27 2007-06-01 Smithkline Beecham Corporation DERIVATIVES OF AZOXOINDOL AS INHIBITORS OF TRK PROTEIN KINASE FOR THE TREATMENT OF CANCER AND CHRONIC PAIN.
AU2003284572A1 (en) * 2002-11-22 2004-06-18 Yamanouchi Pharmaceutical Co., Ltd. 2-oxoindoline derivatives
JP4879492B2 (en) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド Kinase inhibitors for the treatment of diseases
US7517697B2 (en) * 2003-02-05 2009-04-14 Applied Biosystems, Llc Compositions and methods for preserving RNA in biological samples
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
GT200500321A (en) * 2004-11-09 2006-09-04 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASE.
WO2006119148A2 (en) * 2005-04-29 2006-11-09 The Ohio State University Research Foundation Keratinocyte growth factor receptor - tyrosine specific inhibitors for the prevention of cancer metastatis
WO2009030270A1 (en) * 2007-09-03 2009-03-12 Novartis Ag Dihydroindole derivatives useful in parkinson's disease
EP2235004A4 (en) * 2007-12-21 2011-05-04 Univ Health Network Indazolyl, benzimidazolyl, benzotriazolyl substituted indolmone derivatives as kinase inhibitors useful in the treatment of cancer
EP2417127B1 (en) 2009-04-06 2014-02-26 University Health Network Kinase inhibitors and method of treating cancer with same
FR2948940B1 (en) * 2009-08-04 2011-07-22 Servier Lab NOVEL DIHYDROINDOLONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DK2556071T3 (en) 2010-04-06 2016-12-12 Univ Health Network Kinase inhibitors AND THEIR USE FOR THE TREATMENT OF CANCER
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
WO2012142029A2 (en) * 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
PE20150943A1 (en) 2012-09-13 2015-06-20 Hoffmann La Roche 2-OXO-2,3-DIHYDRO-INDOLES FOR THE TREATMENT OF CNS DISORDERS
US9296730B2 (en) 2012-10-26 2016-03-29 Regents Of The University Of Minnesota Aurora kinase inhibitors
CA2927612C (en) 2013-10-18 2022-08-30 University Health Network Treatment for pancreatic cancer
JP6661766B2 (en) * 2015-11-12 2020-03-11 エルジー・ケム・リミテッド Pharmaceutical composition containing a 7-azaindoline-2-one derivative or a pharmaceutically acceptable salt thereof as an active ingredient
US10487054B2 (en) 2017-04-21 2019-11-26 Regents Of The University Of Minnesota Therapeutic compounds
CN113227049A (en) * 2018-10-05 2021-08-06 艾科诺斯科技股份有限公司 Indolinone compounds as MAP4K1 inhibitors
GR1010103B (en) * 2020-07-02 2021-10-18 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, 3-indol-2-ylmethylidene-indolin-2-ones as autotaxin inhibitors
WO2022006412A2 (en) * 2020-07-02 2022-01-06 The Regents Of The University Of Colorado, A Body Corporate Conjugates of ampk inhibitors and protac degraders and related uses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5339992A (en) * 1991-07-10 1994-08-23 Societe De Prospection Et D'inventions Techniques (S.P.I.T. Tubular cartridge for storing and applying a non-solid product, and a drive and thrust assembly for the cartridge
US5374652A (en) * 1990-02-28 1994-12-20 Farmitalia Carlo Erba S R L 2-oxindole compounds which are useful as tyrosine kinase inhibitors
US5382593A (en) * 1992-07-21 1995-01-17 Adir Et Compagnie New 3-(hydroxybenzylidenyl)-indolin-2-ones
US5409949A (en) * 1991-07-12 1995-04-25 Farmitalia Carlo Erba S.R.L. Methylen-oxindole derivatives compositions and tyrosine kinase inhibition therewith
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374652A (en) * 1990-02-28 1994-12-20 Farmitalia Carlo Erba S R L 2-oxindole compounds which are useful as tyrosine kinase inhibitors
US5339992A (en) * 1991-07-10 1994-08-23 Societe De Prospection Et D'inventions Techniques (S.P.I.T. Tubular cartridge for storing and applying a non-solid product, and a drive and thrust assembly for the cartridge
US5409949A (en) * 1991-07-12 1995-04-25 Farmitalia Carlo Erba S.R.L. Methylen-oxindole derivatives compositions and tyrosine kinase inhibition therewith
US5382593A (en) * 1992-07-21 1995-01-17 Adir Et Compagnie New 3-(hydroxybenzylidenyl)-indolin-2-ones
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777417B2 (en) 2001-09-10 2004-08-17 Sugen, Inc. 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors

Also Published As

Publication number Publication date
CA2383623A1 (en) 2000-02-17
WO2000008202A9 (en) 2000-07-27
JP2002522452A (en) 2002-07-23
WO2000008202A2 (en) 2000-02-17
AU5468499A (en) 2000-02-28

Similar Documents

Publication Publication Date Title
WO2000008202A3 (en) 3-methylidenyl-2-indolinone modulators of protein kinase
EP0984930A4 (en) 2-indolinone derivatives as modulators of protein kinase activity
MXPA02008021A (en) Pyrrole substituted 2 indolinone protein kinase inhibitors.
HK1126770A1 (en) Pyrrole substituted 2-indolinone protein kinase inhibitor
WO2001090103A3 (en) 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators
MXPA01006742A (en) 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy.
MY126235A (en) 3-(4-amidopyrrol-2-ylmethylidene) -2- indolinone derivatives as protein kinase inhibitors.
BG104356A (en) Compounds based on azabenzimidazole for the modulation of serin/treonin protein kinase function
WO2001029025A3 (en) Tyrosine kinase inhibitors
WO2001028993A3 (en) Tyrosine kinase inhibitors
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
EP1247803A3 (en) Indolinone compounds suitable for modulation of protein kinases
AU2212299A (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
IL148385A0 (en) Tyrosine kinase inhibitors
HU9803018D0 (en) Methods and compositions for the treatment and prevention of tumors, tumor-veloted disorders and cachexia
WO2003032916A3 (en) Organosulfur inhibitors of tyrosine phosphatases
WO2001042243A3 (en) Protein kinase inhibitors
WO2001083450A3 (en) (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
WO2002028874A3 (en) Tumor proliferation inhibitors
JO2199B1 (en) Substituted pyrroles
WO2002030942A3 (en) Anhydro sugar derivatives of indolocarbazoles
AU2224800A (en) Compositions and methods for the treatment of tumor
WO2000061180A3 (en) Products and methods for treating ptp lar related diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-318, DESCRIPTION, REPLACED BY NEW PAGES 1-334; PAGES 319-345, CLAIMS, REPLACED BY NEW PAGES335-362; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 09762198

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 2383623

Country of ref document: CA